Early study shows Ebola vaccine to be safe
the ONA take:
The Ad5-EBOV Ebola virus vaccine was proven safe in an early study in healthy adults in China, a new study published in the journal The Lancet has shown.
The Phase 1 study evaluated the safety of the vaccine in 120 healthy people in China's Jiangsu province. Participants received either a low dose or high dose of the vaccine, or placebo.
Participants were then monitored for over 28 days for any adverse events and an immune response. Results showed that no serious adverse events occurred and antibodies were significantly increased in participants.
Although the study did not demonstrate whether the immune response lasted longer than 28 days or whether a booster immunization would be needed, researchers say that the vaccine has potential.
Ad5-EBOV is not the only vaccination being studied to combat the Ebola virus, which has killed more 10,000 people since the beginning of 2014.
Other vaccines are currently in Phase III testing where they are being used in people at risk of infection in west Africa. The United Nations Ebola response team said this week that the Ebola outbreak should be gone by this summer.
The Ad5-EBOV Ebola virus vaccine was proven safe in an early study in healthy adults in China.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|